Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Clene Highlights Presentation Of Phase 2 VISIONARY-MS Trial Data At 2024 American Academy of Neurology Annual Meeting; Says 'Long-term CNM-Au8 treatment, encompassing up to three years, was well-tolerated; no significant safety findings were observed'

Author: Benzinga Newsdesk | April 16, 2024 04:06pm

Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)
Significantly improved clinical outcomes associated with long-term daily oral CNM-Au8® 30 mg treatment (change from original baseline; p<0.05)
Long-term CNM-Au8 treatment, encompassing up to three years, was well-tolerated; no significant safety findings were observed
First Phase 2 clinical MS trial of a non-immunomodulatory drug to meet a clinical outcome of improved function supporting remyelination and reparative effects

Posted In: CLNN